Table S3 from Optimization of <i>RAS/BRAF</i> Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer
Cristina Santos, Ramón Salazar(Institut Català d'Oncologia), Bartomeu Massutí(Universitat de Miguel Hernández d'Elx), Mar Varela(Bellvitge University Hospital), Josep Tabernero(Deaconess Hospital), Ma Elena Elez(Universitat Autònoma de Barcelona), José María Viéitez(Hospital Universitario Central de Asturias), Gabriel Capellá(Institut Català d'Oncologia), José Luís Manzano(Badalona Serveis Assistencials), Valentı́ Navarro(Ajuntament de L’Hospitalet), Ferrán Losa, Vı́ctor Moreno(Ajuntament de L’Hospitalet), Rocio García‐Carbonero(Research Institute Hospital 12 de Octubre), Adriana López‐Doriga(Leiden University Medical Center), Pilar Alfonso, Enrique Aranda(Instituto Maimónides de Investigación Biomédica de Córdoba), Alfredo Carrato(Hospital General Universitario de Elche), Xavier Sanjuán, Manuel Valladares(American Society of Clinical Oncology), Clara Montagut(Hospital Del Mar), Auxiliadora Gómez(Instituto Maimónides de Investigación Biomédica de Córdoba), Daniel Azuara(Bellvitge University Hospital)
Cited by 0
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective
|JNCI Journal of the National Cancer Institute|1995|3.4k